The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Characterization of the immune impact of daratumumab by mass cytometry in multiple myeloma
Immune alterations in multiple myeloma (MM) involve several cell types, and so mass cytometry can be utilized to study a diverse set of single cells simultaneously. Here, Gareth Morgan, MD, PhD, FRCP, FRCPath, of the UAMS Myeloma Institute, Little Rock, AR, discusses the immune system profiling of MM using CyTOF mass spectrometry, the new platform that couples mass spectrometry with single-cell flow cytometry, allowing the observation of significant changes to the immune status post-daratumumab (DARA) treatment.
